Posters

      Comparison of Biomarkers of Exposure to Smoke Constituents in Japanese Smokers of Menthol and Non-Menthol Cigarettes

      Lindner, D.; Martin Leroy, C.; Tricker, A. R.
      Conference date
      Sep 6, 2010
      Conference name

      Society for Research on Nicotine and Tobacco (SRNT) Europe 2010
      Link to more information
      Topic
      Summary

      Objective: the objective of this analysis was to compare the levels of biomarkers of exposure (BoExp) to 2-aminonaphthylamine (2-NA), 4-aminobiphenyl (4-ABP), 4 (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), carbon monoxide (CO), nicotine, and pyrene in male and female Japanese smokers of menthol and non-mentholated, cigarettes, and nonsmokers. Methods: post-hoc analysis of data from a multicenter, observational, ambulatory study in male and female Japanese smokers and non-smokers. BoExp were determined in blood for CO (hemoglobin saturation [%COHb]), in plasma for nicotine (plasma cotinine [PCot]), and in 24-h urine for aromatic amines (unmetabolised 2-NA and 4-ABP), nicotine (the molar sum of cotinine, trans-3’-hydroxycotinine, nicotine, and their respective glucuronide conjugates [Neq]), NNK (4-methylnitrosamino)-1-(3-pyridyl)-1-butanol plus glucuronide conjugates [total NNAL]), and pyrene (1-hydroxypyrene plus glucuronide and sulphate conjugates [total 1-OHP]). Nicotine dependence in smokers was assessed using the Fagerström test for nicotine dependence (FTND). Results: the analyzed population consisted of 345 (219 male, 126 female) non-smokers and 648 (417 male, 231 female) smokers including 152 (79 male, 73 female) smokers of menthol cigarettes and 496 (338 male, 158 female) smokers of non-menthol cigarettes. Mean BoExp levels were higher in smokers than in non-smokers: COHb (3.72±1.18 vs. 1.99±0.39 %), PCot (223.61±126.02 vs. 2.50±0.00 ng/ml), Neq (8.04±6.27 vs. 0.34±0.17 mg/day), total NNAL (231.33±194.81 vs. 6.49±7.03 ng/day), total 1-OHP (316.94±238.56 vs. 179.95±575.63 μg/day), 2-NA (19.27±14.78 vs. 3.67±4.05 ng/day), and 4-ABP (12.54±18.07 vs. 3.50±8.48 ng/day). No consistent differences were apparent between menthol vs. Non-menthol smokers: COHb (3.86±1.36 vs. 3.68±1.12 %), PCot (197.70±117.90 vs. 231.54±127.47 ng/ml), Neq (6.84±5.74 vs. 8.41±6.39 mg/day), total NNAL (267.83±249.11 vs. 220.14±173.60 ng/day), total 1-OHP (289.24±208.31 vs. 325.43±246.66 μg/day), 2-NA (17.21±14.51 vs. 19.90±14.82 ng/day), and 4-ABP (11.03±8.89 vs. 13.00±20.05 ng/day). The average FTND score was 4.1±2.1 vs. 4.9±2.0. Trends for increased BoExp levels were generally observed with increasing cigarette tar and nicotine delivery, and number of cigarettes per day (CPD) in smokers of both menthol and non-mentholated cigarettes. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.